News release date: June 23, 2016
Dubai, UAE, June 23, 2016: Endocrine, Metabolic & Immune Disorders – Drug Targets has obtained its first Impact Factor 1.987. The Impact Factor ranking has been awarded by Journal Citation Reports®, which are annually published by the Institute of Scientific Information, a division of Thomson Reuters. Its purpose is to offer a systematic means to critically evaluate the world’s leading journals, with quantifiable, statistical information based on citation data.
Endocrine, Metabolic & Immune Disorders – Drug Targets publishes timely reviews of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders.
For more information, please visit http://benthamscience.com/journals/endocrine-metabolic-and-immune-disorders-drug-targets/